This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.

Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.


Pioglitazone

From Proteopedia

Revision as of 09:20, 11 November 2010 by David Canner (Talk | contribs)
Jump to: navigation, search

Pioglitazone, also known as Actos

Drag the structure with the mouse to rotate

Better Known as: Actos

  • Marketed By: Takeda Pharmaceuticals
  • Major Indication: Hypoglycemia & Type 2 Diabetes
  • Drug Class: PPAR-γ Activator - Thiazolidinedione (Glitazones)
  • Date of FDA Approval (Patent Expiration): 1999 (2011)
  • 2009 Sales: $2.4 Billion [1]
  • Why You Should Care: It is the best selling drug to treat Diabetes and is the 10th best selling drug in the United States.
  • The following is a list of Pharmacokinetic Parameters. See: Pharmaceutical Drugs for more information

References

  1. ↑ http://drugpatentwatch.com/ultimate/preview/tradename/index.php?query=ACTOS


Proteopedia Page Contributors and Editors (what is this?)

David Canner, Alexander Berchansky

Retrieved from "http://52.214.119.220/wiki/index.php/Pioglitazone"
Personal tools